Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
This study, named XALute, is for men with advanced prostate cancer that continues to grow despite standard hormone treatment (metastatic castration-resistant prostate cancer). It is testing a new drug, Xaluritamig, against current commonly used treatments such as Cabazitaxel or other hormone-based medicines (like Abiraterone or Enzalutamide). The main goal is to see if Xaluritamig can help men live longer compared to these existing options. Participants will be carefully monitored throughout the study. This research aims to find better ways to manage this type of prostate cancer and improve patients' lives. Researchers will compare how well Xaluritamig works against the doctor's choice of standard treatment.
Auf einen Blick
Worum geht es in dieser Studie?
This clinical trial is investigating a new treatment called Xaluritamig for men diagnosed with advanced prostate cancer. This specific type of cancer is called 'metastatic castration-resistant prostate cancer,' which means the cancer has spread to other parts of the body (metastatic) and is still growing even after hormone treatment to lower testosterone (castration-resistant).
The main purpose of this study is to compare Xaluritamig with treatments that doctors already use, such as Cabazitaxel or a second type of hormone therapy (like Abiraterone or Enzalutamide). The researchers want to find out if Xaluritamig is better at helping men live longer than these standard options. By conducting this research, doctors hope to discover more effective ways to treat this challenging form of prostate cancer.
Participation in this study could offer access to a new experimental treatment. However, it's important to remember that this is a research study, and we don't yet know if Xaluritamig will be more effective or safer than current treatments. All participants will be closely monitored by a medical team throughout the trial to ensure their safety and track their progress.
Wichtige Erkenntnisse
- Tests a new medicine, Xaluritamig, for advanced prostate cancer.
- Compares Xaluritamig to existing standard treatments.
- Aims to see if Xaluritamig helps men live longer.
- For men whose prostate cancer has spread and is resistant to hormone treatment.
- Requires previous treatment with at least one hormone therapy and one chemotherapy.
Wer könnte berechtigt sein?
This study is looking for men aged 18 or older who have advanced prostate cancer that has spread and is no longer responding to initial hormone treatments. Your doctor must have confirmed your prostate cancer as adenocarcinoma, and it cannot be mixed with other types of cancer.
You must have signs of the cancer getting worse, which could be seen in your blood tests (like PSA levels), scans (like CT, MRI, or bone scans showing new or growing spots), or both. You must have already had surgery to remove your testicles or be receiving ongoing hormone therapy to keep your testosterone levels very low. You also need to have tried at least one hormone-blocking medicine before (like enzalutamide or abiraterone) and had one type of chemotherapy (taxane medicine) for your advanced prostate cancer.
Your general health and ability to perform daily activities need to be good, as assessed by a doctor. Specific types of earlier treatments might affect whether you can join, so your medical history will be carefully reviewed.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Do you have advanced prostate cancer that has spread and kept growing despite hormone treatment?
- Have you already had at least one hormone-blocking medicine and one chemotherapy for your advanced prostate cancer?
- Is your general health good enough for you to manage daily activities?
- Do your scans and blood tests show that your cancer is currently getting worse?
Was beinhaltet die Teilnahme?
If you decide to take part, you will be assigned to receive either the new medicine, Xaluritamig, or one of the standard treatments (Cabazitaxel or another hormone-based medicine chosen by your doctor). You will have regular visits to the clinic for medical check-ups, blood tests, and scans to monitor your health and how the treatment is working. These tests will help the doctors keep track of your cancer and any side effects you might experience.
The specific schedule for visits and tests will depend on the treatment you receive, but you can expect frequent monitoring throughout the study. The total duration of your participation will vary depending on how you respond to the treatment and the study's requirements. You will receive the study medication as directed by the research team. After treatment, there will likely be follow-up appointments to continue monitoring your long-term health and the effects of the treatment.
Potenzielle Risiken und Vorteile
Locations (164)
- Universität von Alabama in BirminghamVerifizierte PostleitzahlBirmingham, Vereinigte Staaten
- City of Hope National Medical CenterVerifizierte PostleitzahlDuarte, Vereinigte Staaten
- Providence Saint Jude Medical CenterVerifizierte PostleitzahlFullerton, Vereinigte Staaten
- Cedars Sinai Medical CenterVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten
- Universität von Kalifornien IrvineVerifizierte PostleitzahlOrange, Vereinigte Staaten
- Universität von Kalifornien San FranciscoVerifizierte PostleitzahlSan Francisco, Vereinigte Staaten
- University of Florida, College of MedicineVerifizierte PostleitzahlGainesville, Vereinigte Staaten
- Sylvester Comprehensive Cancer Center-Fox BuildingVerifizierte PostleitzahlMiami, Vereinigte Staaten
- AdventHealth OrlandoVerifizierte PostleitzahlOrlando, Vereinigte Staaten
- Universität von ChicagoVerifizierte PostleitzahlChicago, Vereinigte Staaten
- Indiana UniversitätVerifizierte PostleitzahlIndianapolis, Vereinigte Staaten
- University of Louisville Health - James Graham Brown Cancer CenterVerifizierte PostleitzahlLouisville, Vereinigte Staaten
Häufige Fragen
What is 'metastatic castration-resistant prostate cancer'?
This means your prostate cancer has spread to other parts of your body (metastatic) and is still growing even though you're receiving hormone treatment to lower your testosterone (castration-resistant).
What is Xaluritamig?
Xaluritamig is a new experimental drug being tested in this study. We are trying to find out if it is a better treatment option for this type of prostate cancer.
What kinds of treatments will Xaluritamig be compared to?
It will be compared to existing treatments like Cabazitaxel (a chemotherapy) or a second type of hormone therapy such as Abiraterone or Enzalutamide.
Will I know which treatment I am getting?
Yes, in this study, you will know if you are receiving Xaluritamig or one of the standard treatments chosen by your doctor.
What is the main goal of the study?
The main goal is to see if Xaluritamig helps men with this type of prostate cancer live longer compared to men receiving the standard treatments.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.